ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...1617181920212223242526...129130»
  • ||||||||||  ivermectin oral / Generic mfg., albendazole / Generic mfg., levamisole / Generic mfg.
    Journal:  Efficacy of clinically used anthelmintics against toxocariasis of buffalo calves in Bangladesh. (Pubmed Central) -  Dec 3, 2022   
    Thirty-two buffalo calves below 3 months of age with clinical Toxocara infection had been selected and treated with albendazole (ABZ), levamisole (LVM) and ivermectin (IVM)...This is a novel information on anthelmintics efficacy in buffalo calves in Bangladesh. Details study is recommended on the efficacy of anthelmintics in different buffalo management systems by in vitro egg hatch assay (EHA) test.
  • ||||||||||  ivermectin oral / Generic mfg.
    Trial initiation date:  Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study) (clinicaltrials.gov) -  Dec 1, 2022   
    P4,  N=100, Not yet recruiting, 
    Details study is recommended on the efficacy of anthelmintics in different buffalo management systems by in vitro egg hatch assay (EHA) test. Initiation date: Sep 2022 --> Jan 2023
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1). (Pubmed Central) -  Nov 29, 2022   
    Practice Point 11: Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting unless it is considered effective against a SARS-CoV-2 variant or subvariant locally in circulation...Practice Point 13: Do not use ciclesonide to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. Practice Point 14: Do not use fluvoxamine to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Systemic veterinary drugs for control of the common bed bug, Cimex lectularius, in poultry farms. (Pubmed Central) -  Nov 19, 2022   
    These findings suggest that systemic ectoparasitic drugs have great potential for practical use to control bed bug infestations in poultry farms. These findings also demonstrate the efficacy of fluralaner (and potentially other isoxazolines) as a potent new active ingredient for bed bug control.
  • ||||||||||  ivermectin oral / Generic mfg.
    Retrospective data, Review, Journal:  Ivermectin role in the prevention of COVID-19: A systematic review and meta-analysis. (Pubmed Central) -  Nov 19, 2022   
    In summary, prophylactic ivermectin did not prevent COVID-19 in the post-exposure population. Although the protective effect of ivermectin was shown in the overall and pre-exposure populations, the results were unreliable owing to poor-quality evidence.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients. (Pubmed Central) -  Nov 16, 2022   
    These results are consistent with recent clinical observations showing that intensive care unit admission was significantly delayed by the combination of AZI and RDV, but not by RDV alone, and could have immediate implications for the treatment of hospitalized patients with COVID-19 as the proposed "drug cocktails" should have antiviral activity against present and future SARS-CoV-2 variants without significant overlapping toxicity, while minimizing the onset of drug resistance. Our results also provide a validated methodology to help sort out which combination of drugs are most likely to be efficacious in vivo, based on their in vitro activity, potential synergy and PK profiles.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2. (Pubmed Central) -  Nov 15, 2022   
    In this study, we revealed that the antifilarial drug ivermectin suppresses HBV production by a different mechanism from the nucleic acid analog entecavir or Na taurocholate co-transporting polypeptide-mediated entry inhibitor cyclosporin A. Ivermectin reduced the levels of several HBV markers, including HBsAg, in HBV-infected human hepatocellular carcinoma cells (HepG2-hNTCP-C4 cells) and humanized mouse hepatocytes (PXB hepatocytes)...These results suggest that KPNA1-6 is involved in the nuclear import of HBV and that ivermectin suppresses the nuclear import of HBV by inhibiting KPNA2. This study demonstrates the potential of ivermectin as a novel treatment for hepatitis B.